Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · IEX Real-Time Price · USD
5.84
+0.11 (1.92%)
At close: Jul 19, 2024, 4:00 PM
5.79
-0.05 (-0.86%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Wave Life Sciences Revenue
Wave Life Sciences had revenue of $112.91M in the twelve months ending March 31, 2024, with 661.49% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $12.54M. In the year 2023, Wave Life Sciences had annual revenue of $113.31M with 3,005.10% growth.
Revenue (ttm)
$112.91M
Revenue Growth
+661.49%
P/S Ratio
6.33
Revenue / Employee
$421,321
Employees
268
Market Cap
715.25M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
Dec 31, 2019 | 15.98M | 1.57M | 10.89% |
Dec 31, 2018 | 14.41M | 10.52M | 270.25% |
Dec 31, 2017 | 3.89M | 2.80M | 256.50% |
Dec 31, 2016 | 1.09M | 940.00K | 618.42% |
Dec 31, 2015 | 152.00K | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Evolus | 219.70M |
Travere Therapeutics | 183.23M |
Weave Communications | 178.08M |
Sage Therapeutics | 91.06M |
Zymeworks | 50.46M |
Arbutus Biopharma | 12.99M |
Stoke Therapeutics | 7.85M |
WVE News
- 26 days ago - What's Going On With Wave Life Sciences Stock On Tuesday? - Benzinga
- 27 days ago - Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease - GlobeNewsWire
- 5 weeks ago - Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing - GlobeNewsWire
- 7 weeks ago - Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer - GlobeNewsWire
- 2 months ago - Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024 - GlobeNewsWire